{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-257538","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.603730+00:00","generated_at":"2026-05-17T01:19:12.450374+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ultragenyx doses first patient in Aurora study of GTX-102 for Angelman; Aspire Phase 3 fully enrolled","bullets":["First patient dosed in global Aurora study (NCT07157254) evaluating GTX-102 (apazunersen) for Angelman syndrome across all genotypes and ages 1 to <65.","Aurora will enroll ~60 participants in four cohorts based on age and genotype; primary endpoints include Bayley-4 and MDRI.","Phase 3 Aspire study fully enrolled with 129 participants (ages 4-17, UBE3A deletion), data expected H2 2026.","Aurora expands patient population beyond deletion-type to include UPD, ICD, and mutation genotypes.","Cohorts A, B, C single-arm; Cohort D randomized 2:1 GTX-102 vs no treatment with crossover at Week 24."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-257538","json":"https://secwatch.observer/filing/0001193125-25-257538.json","markdown":"https://secwatch.observer/filing/0001193125-25-257538.md","text":"https://secwatch.observer/filing/0001193125-25-257538.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000119312525257538/0001193125-25-257538-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000119312525257538/rare-20251030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:19:12.450374+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}